Novo Nordisk A/ S stock (DK0060534915): Wegovy demand, US obesity focus and latest catalysts

Novo Nordisk A/S continues to draw strong attention from global and US investors as demand for its GLP-1–based obesity and diabetes drugs, notably Wegovy and Ozempic, remains high. Recent company updates on capacity expansion, regulatory progress and supply constraints have underscored how central these products are to Novo Nordisk’s medium-term growth outlook, according to Novo Nordisk investor relations as of 04/30/2025 and related company communications in early 2025.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

Novo Nordisk A/S: core business model

Novo Nordisk is a global healthcare company focused primarily on chronic diseases, especially diabetes and obesity. The group develops, manufactures and markets prescription medicines, medical devices and related services that aim to improve long-term disease management. Its portfolio includes insulins, GLP-1 analogs, oral antidiabetic agents and chronic weight management therapies.

The company historically built its franchise around insulin products for type 1 and type 2 diabetes. Over time, it shifted a growing share of research and commercial effort toward GLP-1–based treatments, which stimulate insulin secretion and support blood glucose control. This repositioning has been central to Novo Nordisk’s strategy, as GLP-1 products have shown strong clinical outcomes and commercial potential, especially in major markets like the US.

Beyond diabetes, Novo Nordisk has become a key player in medical obesity management. Its obesity portfolio, including Wegovy, targets patients with elevated body mass index and weight-related comorbidities. The company also maintains activities in rare disease segments such as hemophilia and growth disorders, although these contribute a smaller share of overall revenue compared with diabetes and obesity care.

The business model combines high investment in research and development, large-scale biologics manufacturing and a global commercial infrastructure. Novo Nordisk markets its products through a mix of direct sales, partnerships with healthcare providers and reimbursement negotiations with payors and insurers. The company’s profitability is influenced by patent cycles, pricing regulation and the ability to scale up complex manufacturing processes for injectable therapies.

Main revenue and product drivers for Novo Nordisk A/S

Novo Nordisk’s largest revenue driver is its diabetes care franchise, particularly GLP-1 therapies. The company has reported that GLP-1–based products such as Ozempic and Rybelsus have become leading contributors to sales growth, benefiting from strong uptake in type 2 diabetes patients who seek better glycemic control and potential weight loss. According to company filings for the 2024 financial year published in early 2025, diabetes and obesity care together accounted for the majority of total revenue, with GLP-1 products delivering double-digit growth in many markets, as noted by Novo Nordisk annual reporting as of 01/31/2025.

Obesity care has emerged as a distinct and increasingly important pillar. Wegovy, a higher-dose semaglutide formulation approved for chronic weight management in adults with obesity or overweight and weight-related conditions, has seen robust demand in the US. Capacity constraints and launch sequencing in new markets have been recurring themes in company updates, as Novo Nordisk works to expand production and ensure stable supply. These efforts include investments in manufacturing facilities and contract capacity, which the company has highlighted in capital expenditure plans for 2024 and 2025.

In addition to GLP-1–based therapies, the company continues to generate revenue from modern and human insulins, as well as from insulin pens and delivery devices. While some legacy insulin segments face pricing pressure in the US, the overall portfolio benefits from a broad geographic footprint and product mix. Rare disease treatments, including products for hemophilia and endocrine disorders, contribute incremental revenue and diversify the product base, though they are smaller in scale than the core diabetes and obesity franchises.

From a margin perspective, biologic drugs such as GLP-1s tend to support relatively high gross margins once scale is achieved, but they also require significant upfront investment in production capacity and quality systems. Novo Nordisk’s ability to manage supply, maintain consistent product quality and navigate competitive dynamics in GLP-1 and obesity markets will likely remain crucial for its financial performance over the next several years, especially in the US, where payor policies and reimbursement terms strongly influence net pricing.

Conclusion

Novo Nordisk A/S has evolved from a traditional insulin specialist into a central player in the fast-growing fields of obesity and advanced diabetes treatment. Strong demand for GLP-1 products such as Ozempic and Wegovy, particularly in the US market, underpins the company’s current growth profile but also creates challenges around manufacturing scale and supply stability. For US-focused investors, Novo Nordisk’s NYSE-listed ADRs offer exposure to global trends in metabolic disease management, but the investment case remains sensitive to regulatory decisions, competitive dynamics and the company’s ability to execute on its capacity expansion and product pipeline plans.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.